Heat shock proteins in neurodegenerative diseases: Pathogenic roles and therapeutic implications

International Journal of Hyperthermia

Volumn 25, Issue 8, 2009, Pages 647-654

  Adachi, Hiroaki ^a   Katsuno, Masahisa ^a,b   Waza, Masahiro ^a   Minamiyama, Makoto ^a   Tanaka, Fumiaki ^a   Sobue, Gen ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

Geranylgeranylacetone; Heat shock protein; Hsp90 inhibitor; Neurodegenerative diseases; Ubiquitin proteasome system

Indexed keywords

CHAPERONE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; UBIQUITIN;

DEGENERATIVE DISEASE; HISTOPATHOLOGY; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION;

ANIMALS; DITERPENES; HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; MICE; NEURODEGENERATIVE DISEASES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN FOLDING; UBIQUITIN;

EID: 73649130290     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.3109/02656730903315823     Document Type: Review

References (83)

1. Lagier-Tourenne C, Cleveland DW. Rethinking als: The fus about tdp-43. Cell 2009;136:1001-1004.
2. Lesage S, Brice A. Parkinson's disease: From monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009;18:R48-59.
3. Di Prospero NA, Fischbeck KH. Therapeutics development for triplet repeat expansion diseases. Nat Rev Genet 2005;6:756-765.
4. Katsuno M, Adachi H, Doyu M, Minamiyama M, Sang C, Kobayashi Y, Inukai A, Sobue G. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med 2003;9:768-773.
5. Li M, Miwa S, Kobayashi Y, Merry DE, Yamamoto M, Tanaka F, Doyu M, Hashizume Y, Fischbeck KH, Sobue G. Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Ann Neurol 1998;44:249-254. (Pubitemid 28374114)
6. Katsuno M, Adachi H, Kume A, Li M, Nakagomi Y, Niwa H, Sang C, Kobayashi Y, Doyu M, Sobue G. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 2002;35:843-854.
7. Li M, Nakagomi Y, Kobayashi Y, Merry DE, Tanaka F, Doyu M, Mitsuma T, Hashizume Y, Fischbeck KH, Sobue G. Nonneural nuclear inclusions of androgen receptor protein in spinal and bulbar muscular atrophy. Am J Pathol 1998;153:695-701. (Pubitemid 28419023)
8. Adachi H, Katsuno M, Minamiyama M, Waza M, Sang C, Nakagomi Y, Kobayashi Y, Tanaka F, Doyu M, Inukai A, et al. Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in sbma patients. Brain 2005;128:659-670.
9. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. Chaperone suppression of alpha-synuclein toxicity in a drosophila model for parkinson's disease. Science 2002;295:865-868.
10. Schmidt T, Lindenberg KS, Krebs A, Schols L, Laccone F, Herms J, Rechsteiner M, Riess O, Landwehrmeyer GB. Protein surveillance machinery in brains with spinocerebellar ataxia type 3: Redistribution and differential recruitment of 26s proteasome subunits and chaperones to neuronal intranuclear inclusions. Ann Neurol 2002;51:302-310.
11. Wang J, Farr GW, Zeiss CJ, Rodriguez-Gil DJ, Wilson JH, Furtak K, Rutkowski DT, Kaufman RJ, Ruse CI, Yates JR, et al. Progressive aggregation despite chaperone associations of a mutant sod1-yfp in transgenic mice that develop als. Proc Natl Acad Sci U S A 2009;106:1392-1397.
12. Macario AJ, Conway de Macario E. Sick chaperones, cellular stress, and disease. N Engl J Med 2005;353:1489-1501.
13. Wyttenbach A. Role of heat shock proteins during polyglutamine neurodegeneration: Mechanisms and hypothesis. J Mol Neurosci 2004;23:69-96.
14. Cowan KJ, Diamond MI, Welch WJ. Polyglutamine protein aggregation and toxicity are linked to the cellular stress response. Hum Mol Genet 2003;12:1377-1391.
15. Hay DG, Sathasivam K, Tobaben S, Stahl B, Marber M, Mestril R, Mahal A, Smith DL, Woodman B, Bates GP. Progressive decrease in chaperone protein levels in a mouse model of huntington's disease and induction of stress proteins as a therapeutic approach. Hum Mol Genet 2004;13:1389-1405.
16. Zabel C, Chamrad DC, Priller J, Woodman B, Meyer HE, Bates GP, Klose J. Alterations in the mouse and human proteome caused by huntington's disease. Mol Cell Proteomics 2002;1:366-375.
17. Yamanaka T, Miyazaki H, Oyama F, Kurosawa M, Washizu C, Doi H, Nukina N. Mutant huntingtin reduces hsp70 expression through the sequestration of nf-y transcription factor. EMBO J 2008;27:827-839.
18. Katsuno M, Sang C, Adachi H, Minamiyama M, Waza M, Tanaka F, Doyu M, Sobue G. Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease. Proc Natl Acad Sci U S A 2005;102: 16801-16806.
19. Grunblatt E, Mandel S, Jacob-Hirsch J, Zeligson S, Amariglo N, Rechavi G, Li J, Ravid R, Roggendorf W, Riederer P, et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin- proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm 2004;111:1543-1573.
20. Tsai HF, Lin SJ, Li C, Hsieh M. Decreased expression of hsp27 and hsp70 in transformed lymphoblastoid cells from patients with spinocerebellar ataxia type 7. Biochem Biophys Res Commun 2005;334:1279-1286.
21. Maatkamp A, Vlug A, Haasdijk E, Troost D, French PJ, Jaarsma D. Decrease of hsp25 protein expression precedes degeneration of motoneurons in als-sod1 mice. Eur J Neurosci 2004;20:14-28.
22. Tagawa K, Marubuchi S, Qi ML, Enokido Y, Tamura T, Inagaki R, Murata M, Kanazawa I, Wanker EE, Okazawa H. The induction levels of heat shock protein 70 differentiate the vulnerabilities to mutant huntingtin among neuronal subtypes. J Neurosci 2007;27:868-880.
23. Perutz MF, Pope BJ, Owen D, Wanker EE, Scherzinger E. Aggregation of proteins with expanded glutamine and alanine repeats of the glutamine-rich and asparagine-rich domains of sup35 and of the amyloid beta-peptide of amyloid plaques. Proc Natl Acad Sci U S A 2002;99:5596-5600.
24. Li M, Chevalier-Larsen ES, Merry DE, Diamond MI. Soluble androgen receptor oligomers underlie pathology in a mouse model of spinobulbar muscular atrophy. J Biol Chem 2007;282:3157-3164.
25. Sanchez I, Mahlke C, Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 2003;421:373-379.
26. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004;431:805-810.
27. Wacker JL, Zareie MH, Fong H, Sarikaya M, Muchowski PJ. Hsp70 and hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monomer. Nat Struct Mol Biol 2004;11:1215-1222.
28. Muchowski PJ, Wacker JL. Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 2005;6:11-22.
29. Cummings CJ, Mancini MA, Antalffy B, DeFranco DB, Orr HT, Zoghbi HY. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in sca1. Nat Genet 1998;19:148-154.
30. Kobayashi Y, Kume A, Li M, Doyu M, Hata M, Ohtsuka K, Sobue G. Chaperones hsp70 and hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. J Biol Chem 2000;275:8772-8778.
31. Cummings CJ, Sun Y, Opal P, Antalffy B, Mestril R, Orr HT, Dillmann WH, Zoghbi HY. Over-expression of inducible hsp70 chaperone suppresses neuropathology and improves motor function in sca1 mice. Hum Mol Genet 2001;10:1511-1518.
32. Adachi H, Katsuno M, Minamiyama M, Sang C, Pagoulatos G, Angelidis C, Kusakabe M, Yoshiki A, Kobayashi Y, Doyu M, et al. Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein. J Neurosci 2003;23:2203-2211.
33. Zhang YQ, Sarge KD. Celastrol inhibits polyglutamine aggregation and toxicity though induction of the heat shock response. J Mol Med 2007;85:1421-1428.
34. Kieran D, Kalmar B, Dick JR, Riddoch-Contreras J, Burnstock G, Greensmith L. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in als mice. Nat Med 2004;10:402-405.
35. Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ. Hsp70 reduces alpha-synuclein aggregation and toxicity. J Biol Chem 2004;279:25497-25502.
36. Cleren C, Calingasan NY, Chen J, Beal MF. Celastrol protects against mptp- and 3-nitropropionic acid-induced neurotoxicity. J Neurochem 2005;94:995-1004.
37. Lo Bianco C, Shorter J, Regulier E, Lashuel H, Iwatsubo T, Lindquist S, Aebischer P. Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of parkinson disease. J Clin Invest 2008;118:3087-3097.
38. Bailey CK, Andriola IF, Kampinga HH, Merry DE. Molecular chaperones enhance the degradation of expanded polyglutamine repeat androgen receptor in a cellular model of spinal and bulbar muscular atrophy. Hum Mol Genet 2002;11:515-523.
39. Al-Ramahi I, Lam YC, Chen HK, de Gouyon B, Zhang M, Perez AM, Branco J, de Haro M, Patterson C, Zoghbi HY, et al. Chip protects from the neurotoxicity of expanded and wild-type ataxin-1 and promotes their ubiquitination and degradation. J Biol Chem 2006;281:26714-26724.
40. Adachi H, Waza M, Tokui K, Katsuno M, Minamiyama M, Tanaka F, Doyu M, Sobue G. Chip overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model. J Neurosci 2007;27:5115-5126.
41. Waza M, Adachi H, Katsuno M, Minamiyama M, Sang C, Tanaka F, Inukai A, Doyu M, Sobue G. 17-aag, an hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med 2005;11:1088-1095.
42. Sittler A, Lurz R, Lueder G, Priller J, Lehrach H, Hayer-Hartl MK, Hartl FU, Wanker EE. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of huntington's disease. Hum Mol Genet 2001;10:1307-1315.
43. Agrawal N, Pallos J, Slepko N, Apostol BL, Bodai L, Chang LW, Chiang AS, Thompson LM, Marsh JL. Identification of combinatorial drug regimens for treatment of huntington's disease using drosophila. Proc Natl Acad Sci U S A 2005;102:3777-3781.
44. Fujikake N, Nagai Y, Popiel HA, Okamoto Y, Yamaguchi M, Toda T. Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones. J Biol Chem 2008;283:26188-26197.
45. Dou F, Netzer WJ, Tanemura K, Li F, Hartl FU, Takashima A, Gouras GK, Greengard P, Xu H. Chaperones increase association of tau protein with microtubules. Proc Natl Acad Sci U S A 2003;100:721-726.
46. Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, De Lucia M, McGowan E, Lewis J, Prihar G, et al. Chip and hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet 2004;13:703-714.
47. Benussi L, Ghidoni R, Paterlini A, Nicosia F, Alberici AC, Signorini S, Barbiero L, Binetti G. Interaction between tau and alpha-synuclein proteins is impaired in the presence of p301l tau mutation. Exp Cell Res 2005;308:78-84.
48. Batulan Z, Taylor DM, Aarons RJ, Minotti S, Doroudchi MM, Nalbantoglu J, Durham HD. Induction of multiple heat shock proteins and neuroprotection in a primary culture model of familial amyotrophic lateral sclerosis. Neurobiol Dis 2006;24:213-225.
49. Kiaei M, Kipiani K, Petri S, Chen J, Calingasan NY, Beal MF. Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. Neurodegener Dis 2005;2:246-254. (Pubitemid 43805908)
50. Auluck PK, Bonini NM. Pharmacological prevention of parkinson disease in drosophila. Nat Med 2002;8:1185-1186.
51. Auluck PK, Meulener MC, Bonini NM. Mechanisms of suppression of {alpha}-synuclein neurotoxicity by geldanamycin in drosophila. J Biol Chem 2005;280:2873-2878.
52. Flower TR, Chesnokova LS, Froelich CA, Dixon C, Witt SN. Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of parkinson's disease. J Mol Biol 2005;351:1081-1100.
53. Hirakawa T, Rokutan K, Nikawa T, Kishi K. Geranylgeranylacetone induces heat shock proteins in cultured guinea pig gastric mucosal cells and rat gastric mucosa. Gastroenterology 1996;111:345-357. (Pubitemid 26256722)
54. Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood) 2003;228:111-133.
55. Sullivan W, Stensgard B, Caucutt G, Bartha B, McMahon N, Alnemri ES, Litwack G, Toft D. Nucleotides and two functional states of hsp90. J Biol Chem 1997;272:8007-8012.
56. Neckers L. Heat shock protein 90 inhibition by 17-allylamino- 17- demethoxygeldanamycin: A novel therapeutic approach for treating hormone-refractory prostate cancer. Clin Cancer Res 2002;8:962-966.
57. Egorin MJ, Zuhowski EG, Rosen DM, Sentz DL, Covey JM, Eiseman JL. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17- demethoxygeldanamycin (nsc 330507) in cd2f1 mice1. Cancer Chemother Pharmacol 2001;47:291-302.
58. McClellan AJ, Scott MD, Frydman J. Folding and quality control of the vhl tumor suppressor proceed through distinct chaperone pathways. Cell 2005;121:739-748.
59. Dickey CA, Kamal A, Lundgren K, Klosak N, Bailey RM, Dunmore J, Ash P, Shoraka S, Zlatkovic J, Eckman CB, et al. The high-affinity hsp90-chip complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest 2007;117:648-658.
60. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002;8:S55-61.
61. Tokui K, Adachi H, Waza M, Katsuno M, Minamiyama M, Doi H, Tanaka K, Hamazaki J, Murata S, Tanaka F, et al. 17- dmag ameliorates polyglutamine- mediated motor neuron degeneration through well-preserved proteasome function in an sbma model mouse. Hum Mol Genet 2009;18:898-910.
62. Cuervo AM, Dice JF. A receptor for the selective uptake and degradation of proteins by lysosomes. Science 1996;273:501-503.
63. Cuervo AM, Dice JF. Lysosomes, a meeting point of proteins, chaperones, and proteases. J Mol Med 1998;76:6-12.
64. Qing G, Yan P, Xiao G. Hsp90 inhibition results in autophagy-mediated proteasome-independent degradation of ikappab kinase (ikk). Cell Res 2006;16:895-901.
65. Finn PF, Mesires NT, Vine M, Dice JF. Effects of small molecules on chaperone-mediated autophagy. Autophagy 2005;1:141-145.
66. Shen S, Zhang P, Lovchik MA, Li Y, Tang L, Chen Z, Zeng R, Ma D, Yuan J, Yu Q. Cyclodepsipeptide toxin promotes the degradation of hsp90 client proteins through chaperonemediated autophagy. J Cell Biol 2009;185:629-639.
67. Luo W, Dou F, Rodina A, Chip S, Kim J, Zhao Q, Moulick K, Aguirre J, Wu N, Greengard P, et al. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc Natl Acad Sci U S A 2007;104:9511-9516.
68. Wang L, Xie C, Greggio E, Parisiadou L, Shim H, Sun L, Chandran J, Lin X, Lai C, Yang WJ, et al. The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci 2008;28:3384-3391.
69. Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, Orr HT, Paulson HL, Yang L, Kotin RM, Davidson BL. Rnai suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 2004;10:816-820.
70. Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q, Yang L, Kotin RM, Paulson HL, Davidson BL. Rna interference improves motor and neuropathological abnormalities in a huntington's disease mouse model. Proc Natl Acad Sci U S A 2005;102:5820-5825.
71. Raoul C, Abbas-Terki T, Bensadoun JC, Guillot S, Haase G, Szulc J, Henderson CE, Aebischer P. Lentiviral-mediated silencing of sod1 through rna interference retards disease onset and progression in a mouse model of als. Nat Med 2005;11:423-428.
72. La Spada AR, Weydt P. Targeting toxic proteins for turnover. Nat Med 2005;11:1052-1053.
73. Hegde AN, Upadhya SC. The ubiquitin-proteasome pathway in health and disease of the nervous system. Trends Neurosci 2007;30:587-595.
74. Ciechanover A, Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: Sometimes the chicken, sometimes the egg. Neuron 2003;40:427-446.
75. Jana NR, Zemskov EA, Wang G, Nukina N. Altered proteasomal function due to the expression of polyglutamine- expanded truncated n-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 2001;10:1049-1059.
76. Seo H, Sonntag KC, Isacson O. Generalized brain and skin proteasome inhibition in huntington's disease. Ann Neurol 2004;56:319-328.
77. Bennett EJ, Bence NF, Jayakumar R, Kopito RR. Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol Cell 2005;17:351-365.
78. Bennett EJ, Shaler TA, Woodman B, Ryu KY, Zaitseva TS, Becker CH, Bates GP, Schulman H, Kopito RR. Global changes to the ubiquitin system in huntington's disease. Nature 2007;448:704-708.
79. Ding Q, Lewis JJ, Strum KM, Dimayuga E, Bruce-Keller AJ, Dunn JC, Keller JN. Polyglutamine expansion, protein aggregation, proteasome activity, and neural survival. J Biol Chem 2002;277:13935-13942.
80. Diaz-Hernandez M, Hernandez F, Martin-Aparicio E, Gomez-Ramos P, Moran MA, Castano JG, Ferrer I, Avila J, Lucas JJ. Neuronal induction of the immunoproteasome in huntington's disease. J Neurosci 2003;23:11653-11661.
81. Wang J, Wang CE, Orr A, Tydlacka S, Li SH, Li XJ. Impaired ubiquitin-proteasome system activity in the synapses of huntington's disease mice. J Cell Biol 2008;180: 1177-1189.
82. Bowman AB, Yoo SY, Dantuma NP, Zoghbi HY. Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation. Hum Mol Genet 2005;14:679-691.
83. Bett JS, Goellner GM, Woodman B, Pratt G, Rechsteiner M, Bates, GP. Proteasome impairment does not contribute to pathogenesis in r6/2 huntington's disease mice: Exclusion of proteasome activator reg{gamma} as a therapeutic target. Hum Mol Genet 2006;15:33-44.